---
document_datetime: 2025-12-16 08:19:30
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/agamree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: agamree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.8642059
conversion_datetime: 2025-12-29 23:06:35.811142
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## AGAMREE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 30/10/2025                          |                                             | SmPC                             | Update of sections 4.6 and 5.3 of the SmPC in order |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000280104                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.6 and 5.3 of the SmPC in order to update information and recommendations regarding pregnancy based on results from a dose range finding embryo-fetal developmental toxicity study of vamorolone by the oral (gavage) route in the female CD-1 IGS mice (study 20496186).   |            |     | to update information and recommendations regarding pregnancy based on results from a dose range finding embryo-fetal developmental toxicity study of vamorolone by the oral (gavage) route in the female CD-1 IGS mice (study 20496186); the Package Leaflet is updated accordingly.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000308122 | This was an application for a group of variations. B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted            | 28/10/2025 | N/A |                                                                                                                                                                                                                                                                                         |
| Variation type IB / EMA/VR/0000303155 | B.II.e.2 Change in the specification parameters and/or limits of the immediate                                                                                                                                                                                                                                                                                                                                                                                                    | 22/10/2025 | N/A |                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                                       | packaging of the finished product - B.II.e.2.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000294402 | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.f Minor change in the manufacturing process of an aqueous oral suspension - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the | 01/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| product - B.II.b.1.e Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for nonsterile medicinal products - Accepted  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted  B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted  B.II.b.2 Change to importer, batch release  arrangements and quality control testing of  the finished product - B.II.b.2.a  Replacement or addition of a site where  batch control/testing takes place - Accepted  B.II.b.4 Change in the batch size (including  batch size ranges) of the finished product -   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000284698 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted A grouped application consisting of: C.I.13: Submission of the final report from study SNT-I-VAM-025. This is a phase I, open- label, single-arm study to evaluate the CYP3A4 induction potential of vamorolone on the pharmacokinetics of midazolam (a sensitive CYP3A4 probe) in healthy subjects. C.I.13: Submission of the final report from study SNT-I-VAM-026. This is a phase I, open-label, randomized, 3-arm, parallel- group,positive- and negative-arm controlled study to evaluate the mineralocorticoid | 18/09/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | healthy subjects.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000286394 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.e Update of the test procedure to comply with the updated | 25/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.a Tightening of specification limits - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.c Deletion of a non-significant specification parameter (e.g. deletion of an obsolete   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000278803 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.f Minor change in the manufacturing process of an aqueous oral suspension - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/07/2025 | N/A |
| Variation type IB / EMA/VR/0000263794 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | C.I.z - To provide an updated environmental risk assessment (ERA) report.                                                   |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000248412 | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.z Other changes - Accepted | 26/02/2025 | N/A |             |
| PSUR / EMA/PSUR/0000248446            | - -                                                                                                                         |            |     | Maintenance |
| PSUR / EMA/PSUR/0000288222            | - -                                                                                                                         |            |     | Maintenance |